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Necrotizing enterocolitis (NEC) is the leading cause of death from gastrointestinal 
disease in premature infants. NEC is characterized by an exaggerated pro-inflammatory 
response, gut barrier dysfunction and impaired mucosal healing. Interleukin-22 
(IL-22) has been shown to provide gut barrier maintenance and attenuate intestinal 
inflammation in adult animal models. Therefore, we hypothesized that IL-22 plays a role 
in protecting against NEC by reducing intestinal inflammation. We evaluated IL-22 as 
a treatment strategy in vivo using a NEC mouse model, which utilizes a combination of 
formula feedings and hypoxia. We used breastfed (BF) mice as a healthy negative control 
and formula-fed (FF) NEC mice as a sick positive control. Our results supported our 
hypothesis of the role of IL-22 in protecting against NEC. We found disruption of the 
small intestinal architecture in the histology of NEC FF compared to the BF controls. 
Importantly, in the NEC mice that received treatment with IL-22, we found restoration 
in gross appearance of the intestine and improvement in the intestinal architecture 
compared to NEC FF mice and they appeared similar to the BF controls. We further 
found that treatment with IL-22 increases the expression of CD4+ T helper cells, which 
suggests that these T helper cells are mediating protection against the intestine. Taken 
together, we conclude that IL-22 contributes to protection against NEC, which may be 
related to enhanced immune cell expression in the gut. This raises the possibility that 
treatment with IL-22 may protect premature infants from NEC.
